Hagens Berman Notifies Investors of Extended Class Period and May 5, 2014 Lead Plaintiff Deadline in Galena Biopharma, Inc. Securities Fraud Class Actions

News provided by

Apr 07, 2014, 05:23 ET

BERKELEY, Calif., April 7, 2014 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP reminds investors of the May 5, 2014 deadline to file for lead plaintiff in a securities fraud case against Galena Biopharma, Inc. (NASDAQ: GALE) ("Galena" or "the Company"). The Class Period has been extended to cover investors who bought stock between May 9, 2013 and March 17, 2014 (the "Class Period"). Investors who purchased Galena securities during the Class Period may contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000, emailing [email protected] or visiting http://hb-securities.com/investigations/Galena.

The complaints, which were filed in the U.S. District Court for the District of Oregon, will likely be consolidated into one class action upon appointment of the lead plaintiff, and generally allege that unbeknownst of investors, Galena hired The DreamTeam Group and Mission IR, two affiliated promotional agents, to pump up the value of Galena common stock during the Class Period. This endeavor, which ran for 240 days and ended in March 2014, included a campaign of planting fraudulent analyst reports and news articles that touted the company, its product pipeline and a drug marketed and manufactured by the company, Abstral, according to the complaints.

The complaints state that in many instances, these fraudulent media reports were written under aliases. In all instances, the authors never revealed that they were paid by DreamTeam to write these media reports or that Galena had complete editorial control over their work, the complaints state. The placement of these fraudulent media reports coincided with positive company announcements, such as successful clinical trials and the launch of Abstral, so as to have maximum impact upon Galena's share price, complaints state.

The complaints allege that during this time, when Galena's stock price was artificially inflated, Galena's officers and directors sold nearly $10 million worth of Galena stock.

On March 17, 2014 Galena revealed that the company learned in February that the SEC is investigating "certain matters related to our company and an outside investor-relations firm that we retained in 2013." Galena's shares dropped more than nine percent in after-hours trading following the company's announcement of the SEC investigation on March 17, 2014.

The deadline to file for lead plaintiff in the securities fraud class action is May 5, 2014.

Persons with non-public information regarding Galena should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC Whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email one of the links above.

About Hagens Berman
Hagens Berman Sobol Shapiro LLP is an investor-rights class-action law firm with offices in nine cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the law firm and its successes can be found at www.hb-securities.com. Read the Firm's Securities Newsletter at http://www.hb-securities.com/newsletter. The firm's blog is located at www.meaningfuldisclosure.com.

Contacts
Firmani + Associates
Mark Firmani, 206-443-9357
[email protected]

SOURCE Hagens Berman Sobol Shapiro LLP